🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
17/05/2023 18,26 18,64 17,68 18,19 -0,55% 5,26% 895.000
16/05/2023 18,93 19,07 17,78 18,29 -6,30% 6,81% 967.200
15/05/2023 18,79 20,44 18,53 19,52 +5,63% 10,16% 1.283.000
12/05/2023 18,10 18,55 17,96 18,48 +2,55% 3,26% 589.600
11/05/2023 18,56 18,86 18,02 18,02 -4,20% 4,53% 699.200
10/05/2023 19,26 19,91 18,36 18,81 -3,04% 8,05% 1.005.700
09/05/2023 19,70 20,08 19,38 19,40 -2,27% 3,55% 1.056.300
08/05/2023 19,66 19,89 18,96 19,85 +1,48% 4,73% 1.186.600
05/05/2023 19,62 19,83 19,29 19,56 +0,36% 2,75% 729.400
04/05/2023 18,48 19,55 18,08 19,49 +5,01% 7,95% 874.700
03/05/2023 17,68 18,69 17,68 18,56 +4,04% 5,71% 1.079.100
02/05/2023 18,35 18,42 17,75 17,84 -3,25% 3,65% 781.400
01/05/2023 17,75 18,54 17,63 18,44 +3,31% 5,13% 545.900
28/04/2023 17,42 18,12 17,02 17,85 +1,94% 6,31% 549.700
27/04/2023 18,12 18,12 17,40 17,51 -2,67% 3,97% 558.100
26/04/2023 18,42 18,69 17,83 17,99 -2,44% 4,67% 555.400
25/04/2023 19,12 19,48 18,37 18,44 -4,51% 5,83% 548.300
24/04/2023 19,82 19,82 18,82 19,31 -3,40% 5,05% 620.300
21/04/2023 19,25 20,22 18,86 19,99 +4,33% 7,06% 966.500
20/04/2023 18,99 19,48 18,63 19,16 -0,10% 4,50% 1.066.900
19/04/2023 18,44 19,59 18,15 19,18 +2,68% 7,81% 1.031.700
18/04/2023 19,08 19,34 18,43 18,68 -1,48% 4,77% 916.200
17/04/2023 17,67 19,03 17,54 18,96 +8,10% 8,40% 1.419.500
14/04/2023 18,32 18,38 17,33 17,54 -4,98% 5,76% 597.300
13/04/2023 17,06 18,64 17,04 18,46 +8,78% 9,35% 1.110.900
12/04/2023 17,94 17,94 16,94 16,97 -4,12% 5,57% 536.800
11/04/2023 17,26 17,89 17,24 17,70 +1,96% 3,77% 647.600
10/04/2023 17,33 17,86 17,18 17,36 -1,20% 3,92% 718.900
06/04/2023 17,95 18,03 17,46 17,57 -1,46% 3,18% 594.400
05/04/2023 17,81 18,22 17,60 17,83 -0,34% 3,45% 436.500